EFFECTIVENESS AND TOLERABILITY OF 12-WEEK TREATMENT WITH MICRONIZED FENOFIBRATE 200MG IN A DRUG-MONITORING PROGRAM INVOLVING 9884 PATIENTS WITH DYSLIPIDEMIA

Following the introduction of micronised fenofibrate (Laboratoires Fou rnier, Dijon), a new formulation of fenofibrate with an improved pharm acokinetic profile allowing convenient once-daily administration, we p erformed a drug-monitoring programme in Germany to evaluate the effect iveness and tolerability of 12-week treatment with micronised fenofibr ate 200mg in a large sample of patients with various types of dyslipid aemia. In total, 9884 patients were included, and 9503 patients were a vailable for evaluation of effectiveness. In this unselected patient p opulation, micronised fenofibrate 200mg lowered total cholesterol by 2 0%, low density lipoprotein (LDL) cholesterol by 25%, triglycerides by 28%, and increased high density lipoprotein (HDL) cholesterol by 23%. The LDL/HDL ratio was lowered from a mean of 5.3 to 3.2 after 12 week s. Effectiveness was further analysed retrospectively in a series of p atient populations including different types of dyslipidaemia, type 2 diabetics, and patients with previous myocardial infarction. These ana lyses were consistent with the results found in the overall population . Treatment with micronised fenofibrate was generally very well tolera ted, with 3.8% of patients experiencing adverse events. No adverse rea ctions were observed that were previously unknown for fenofibrate. The results from this large drug-monitoring programme confirmed the thera peutic interest in micronised fenofibrate in different types of dyslip idaemias and patient populations under the conditions of everyday medi cal practice.